Vanda Posts $1.04/Shr Loss in Q2, Deepening Cash Burn Concerns
VNDA sits 17% above its 52-week low of $4.14.
Summary
Vanda reported a Q2 loss of $1.04 per share, a sharp deterioration from the already significant losses flagged in its Q1 filing. The company is burning cash fast, with a $306M market cap and an active $200M shelf registration — this loss rate puts pressure on its runway. The result lands against a backdrop of recent regulatory wins (FDA rare pediatric disease designation for VCA-894A, EMA orphan drug status for imsidolimab), but those are early-stage and won't offset near-term cash consumption. The Q1 10-Q already showed accelerating losses; this Q2 print confirms the trend is worsening.
Updates
· SEC 10-Q — Q2 net loss was $62.5M on revenue of $50.5M; HETLIOZ sales fell to $5.6M from $16.2M a year earlier. Cash and marketable securities totaled $170.0M at June 30.
At the time of this announcement, VNDA was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $306.1M. The 52-week trading range was $4.14 to $9.94. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.